Selection of phase II/III breast cancer study highlights at the 2022 ESMO annual meeting Maximilian Marhold short review Open access 20 April 2023 Pages: 94 - 96
ESMO 2022 personal non-small lung cancer (NSCLC) highlights Lena HorvathGeorg Pall short review 05 May 2023 Pages: 97 - 99
ESMO 2022: spotlight on new emerging treatment options in central nervous system tumors Maximilian J. MairAnna S. Berghoff short review Open access 20 March 2023 Pages: 100 - 104
ESMO update: upper gastrointestinal cancer Elisabeth S. BergenAysegül Ihan-Mutlu short review Open access 05 May 2023 Pages: 105 - 107
Immunotherapy for metastatic melanoma—from little benefit to first-line treatment Christiane G. Mutz-RablPeter KoelblingerLukas Koch short review Open access 03 May 2023 Pages: 108 - 112
Lessons learned in adjuvant colorectal cancer Theresa SchmalfussHossein Taghizadeh short review Open access 28 April 2023 Pages: 113 - 115
Molecular pathology of colorectal cancer Petar NoackRupert Langer review Open access 27 April 2023 Pages: 116 - 121
Excellent response of a disseminated SMARCA4-deficient thoracic sarcomatoid tumor to immunochemotherapy—a case report Clemens PetraschSimon UdovicaAndrea Kaufmann-Keck case report 20 April 2023 Pages: 122 - 124
Neoadjuvant and adjuvant therapy in early breast cancer. A short review on current clinical approaches Simon UdovicaKathrin Strasser-Weippl short review 08 May 2023 Pages: 125 - 128
Spectrum of renal involvement in MGRS patients: a 6-year study Poornima TadkalVishwanath SiddiniMallikarjun Kalashetty original report 23 February 2023 Pages: 129 - 134
Position paper on CDK4/6 inhibitors in early breast cancer Michael GnantChristian F. SingerRupert Bartsch position paper Open access 14 March 2023 Pages: 135 - 144